22nd Century Group, Inc. (NYSEMKT:XXII) announced that the Company filed a Form S-3 shelf registration statement on April 18th with the U.S. Securities and Exchange Commission (“SEC”). Upon SEC approval, the universal shelf registration will allow, but not compel, 22nd Century Group to raise up to $45 million of capital over a three-year period through a wide array of securities at amounts and at increments to be determined by the Company. 22nd Century Group Inc (NYSEMKT:XXII) shares after opening at $2.98 moved to $2.98 on last trade day and at the end of the day closed at $2.48. Company price to sales ratio in past twelve months was calculated as 19.79 and price to cash ratio as 24.91. 22nd Century Group Inc (NYSEMKT:XXII) showed a negative weekly performance of -12.37%.
Investors who acquired stake in Acceleron Pharma Inc (NASDAQ:XLRN) before its IPO have agreed to sell their stake to a major drugmaker that is seeking to up its stake in the company.The early investors to cash in on their holding, through sale toCelgene Corporation (NASDAQ:CELG), include Flagship Ventures, Venrock, Alkermes Inc, Advanced Technology Ventures and Polaris Venture Partners. The sellers will be offering combined total of 1.1 million shares of Acceleron. They all acquired the shares before the September IPO, during which the shares were offered at $15. Currently the shares are trading in the range of $39 per piece. Acceleron Pharma Inc (NASDAQ:XLRN) shares fell -5.31% in last trading session and ended the day on $36.37. XLRN return on equity ratio is recorded as 37.10% and its return on assets is -48.80%.
BMO Capital Markets started coverage on shares of Applied Genetic Technologies Corp (NASDAQ:AGTC) in a research note issued on Monday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating and a $14.08 price target on the stock.Applied Genetic Technologies Corp (NASDAQ:AGTC) shares moved down -5.40% in last trading session and was closed at $13.32, while trading in range of $12.91-$14.32. Applied Genetic Technologies Corp (NASDAQ:AGTC) year to date performance is -9.76%.
Oragenics Inc (NYSEMKT:OGEN) wil announce it earning tomorrow. Oragenics Inc (NYSEMKT:OGEN) weekly performance is -12.60%. On last trading day company shares ended up $2.22. Oragenics Inc (NYSEMKT:OGEN) distance from 50-day simple moving average is -28.46%. Analysts mean target price for the company is $7.00.